Axsome Therapeutics Inc
NASDAQ:AXSM
Gross Margin
Axsome Therapeutics Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Axsome Therapeutics Inc
NASDAQ:AXSM
|
5.2B USD |
91%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
831.3B USD |
81%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
373.7B USD |
68%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
85%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
213.3B CHF |
74%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
190.1B CHF |
75%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
156.3B GBP |
82%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
210.3B USD |
79%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
68%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
116.9B EUR |
70%
|
Axsome Therapeutics Inc
Glance View
Axsome Therapeutics Inc. emerged as a dynamic player in the biopharmaceutical arena, driven by a resolute commitment to alleviate the burdensome effects of central nervous system (CNS) disorders. Founded with a vision to fill critical treatment gaps in neurologically influenced conditions, Axsome leverages innovative drug discovery and development to address medical needs that have long been underserved. The company focuses intently on conditions such as depression, migraine, narcolepsy, and Alzheimer's disease-related agitation, channeling resources into a streamlined pipeline that seeks to fast-track the development and commercialization of life-changing therapies. Operating at the intersection of cutting-edge science and patient-centric healthcare, Axsome generates revenue through the successful approval and marketing of its proprietary pharmaceutical products. The company's business model hinges on advancing its clinical candidates through rigorous trials, eventually gaining the necessary regulatory endorsements to bring them to market. By holding the intellectual property rights for these novel drugs, Axsome enjoys the advantages of exclusivity in the marketplace, which allows it to negotiate favorable pricing and reimbursement terms. This strategic approach not only positions Axsome as a potentially transformative force within the pharmaceutical industry but also underlines its commitment to producing viable, accessible treatments for those grappling with debilitating CNS disorders.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Axsome Therapeutics Inc's most recent financial statements, the company has Gross Margin of 91.4%.
You don't have any saved screeners yet